ARTV (Artiva Biotherapeutics) ROCE %: -91.79% (As of Mar. 2026)


ARTV Artiva Biotherapeutics Inc ARTV
12 GF Score
Price $8.83
! 3 Warning Signs
View Full Analysis

What is Artiva Biotherapeutics ROCE %?

Artiva Biotherapeutics ARTV -5.16% 12 ROCE % is -91.79% as of Mar. 2026. GuruFocus rates ARTV with a GF Score™ of 12/100. The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Artiva Biotherapeutics's annualized ROCE % for the quarter that ended in Mar. 2026 was -91.79%.

Artiva Biotherapeutics  (NAS:ARTV) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Artiva Biotherapeutics ROCE % Related Terms

Artiva Biotherapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Artiva Biotherapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Artiva Biotherapeutics ROCE % Chart

Artiva Biotherapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -82.51 -46.37 -30.62 -46.37 -56.99

Artiva Biotherapeutics Quarterly Data
Dec19 Dec20 Mar21 Sep21 Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -47.12 -54.04 -61.81 -68.65 -91.79
ARTV
12GF Score
Artiva Biotherapeutics Inc ARTV
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Artiva Biotherapeutics ROCE % Calculation

Artiva Biotherapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-89.81/( ( (209.581 - 12.253) + (130.94 - 13.087) )/ 2 )
=-89.81/( (197.328+117.853)/ 2 )
=-89.81/157.5905
=-56.99 %

Artiva Biotherapeutics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-97.72/( ( (130.94 - 13.087) + (105.955 - 10.88) )/ 2 )
=-97.72/( ( 117.853 + 95.075 )/ 2 )
=-97.72/106.464
=-91.79 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -91.79% mean?
Artiva Biotherapeutics (ARTV) has a ROCE % of -91.79% as of Mar. 2026.
Is Artiva Biotherapeutics' ROCE % too high?
Artiva Biotherapeutics' current ROCE % is -91.79%. Overall, Artiva Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Artiva Biotherapeutics' ROCE % compare to ENTA and VNDA?
Artiva Biotherapeutics' ROCE % of -91.79% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Artiva Biotherapeutics's current ROCE % is -91.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artiva Biotherapeutics stock overvalued right now?
Artiva Biotherapeutics (ARTV) has a current ROCE % of -91.79%. The current ROCE % is -91.79%. Artiva Biotherapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Artiva Biotherapeutics (ARTV), the current ROCE % is -91.79% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Artiva Biotherapeutics Business Description

Address 5505 Morehouse Drive, Suite 100, San Diego, CA, USA, 92121
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
12GF Score

Get the complete analysis for ARTV

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.83
Price